NDC-11 (Package) | NDC-9 (Product) | Generic Name (Ascending) | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
51655-0860-26 | 51655-0860 | ESTRADIOL | ESTRADIOL | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | May 4, 2023 | In Use | ||
70518-3818-00 | 70518-3818 | ESTRADIOL | ESTRADIOL | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Aug. 3, 2023 | In Use | ||
00517-0420-01 | 00517-0420 | ESTRADIOL VALERATE | ESTRADIOL VALERATE | 20.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | March 1, 2020 | In Use | ||
00517-0440-01 | 00517-0440 | ESTRADIOL VALERATE | ESTRADIOL VALERATE | 40.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | March 1, 2020 | In Use | ||
70700-0273-22 | 70700-0273 | ESTRADIOL VALERATE | Estradiol valerate | 10.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | May 1, 2023 | In Use | ||
70700-0274-22 | 70700-0274 | ESTRADIOL VALERATE | Estradiol valerate | 20.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | May 1, 2023 | In Use | ||
70700-0275-22 | 70700-0275 | ESTRADIOL VALERATE | Estradiol valerate | 40.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | May 1, 2023 | In Use | ||
44278-0025-30 | 44278-0025 | EXEMESTANE | Exemestane | 25.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Nov. 22, 2013 | In Use | ||
73491-0627-01 | 73491-0627 | Efbemalenograstim alfa-vuxw | RYZNEUTA | 20.0 mg/mL | Immunotherapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov. 23, 2023 | In Use | |
76961-0101-01 | 76961-0101 | Eflapegrastim-xnst | Rolvedon | 13.2 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte colony stimulating factor | Subcutaneous | Oct. 18, 2022 | In Use | |
72187-0101-03 | 72187-0101 | Elacestrant | ORSERDU | 86.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ERα | Oral | Jan. 27, 2023 | In Use | |
72187-0102-03 | 72187-0102 | Elacestrant | ORSERDU | 345.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ERα | Oral | Jan. 27, 2023 | In Use | |
00003-2291-11 | 00003-2291 | Elotuzumab | Empliciti | 300.0 mg/1 | Immunotherapy | Monoclonal Antibody | SLAMF7 | Intravenous | Nov. 30, 2015 | In Use | |
00003-4522-11 | 00003-4522 | Elotuzumab | Empliciti | 400.0 mg/1 | Immunotherapy | Monoclonal Antibody | SLAMF7 | Intravenous | Nov. 30, 2015 | In Use | |
63539-0252-02 | 63539-0252 | Elranatamab-bcmm | Elrexfio | 44.0 mg/1.1mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Aug. 15, 2023 | In Use | |
00069-4494-02 | 00069-4494 | Elranatamab-bcmm | Elrexfio | 76.0 mg/1.9mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Aug. 15, 2023 | In Use | |
00069-2522-02 | 00069-2522 | Elranatamab-bcmm | Elrexfio | 44.0 mg/1.1mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Aug. 15, 2023 | In Use | |
59572-0705-30 | 59572-0705 | Enasidenib mesylate | Idhifa | 50.0 mg/1 | Chemotherapy | Enzyme Inhibitor | IDH2 | Oral | Aug. 1, 2017 | In Use | |
59572-0710-30 | 59572-0710 | Enasidenib mesylate | Idhifa | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | IDH2 | Oral | Aug. 1, 2017 | In Use | |
70255-0025-01 | 70255-0025 | Encorafenib | BRAFTOVI | 75.0 mg/1 | Chemotherapy | BRAF Inhibitor | V600E | Oral | June 27, 2018 | In Use | |
70255-0025-03 | 70255-0025 | Encorafenib | BRAFTOVI | 75.0 mg/1 | Chemotherapy | BRAF Inhibitor | V600E | Oral | June 27, 2018 | In Use | |
70255-0025-05 | 70255-0025 | Encorafenib | BRAFTOVI | 75.0 mg/1 | Chemotherapy | BRAF Inhibitor | V600E | Oral | Aug. 3, 2020 | In Use | |
70255-0025-06 | 70255-0025 | Encorafenib | BRAFTOVI | 75.0 mg/1 | Chemotherapy | BRAF Inhibitor | V600E | Oral | Aug. 3, 2020 | In Use | |
70255-0020-01 | 70255-0020 | Encorafenib | BRAFTOVI | 50.0 mg/1 | Chemotherapy | BRAF Inhibitor | V600E | Oral | June 27, 2018 | March 13, 2019 | In Use |
00469-0125-99 | 00469-0125 | Enzalutamide | Xtandi | 40.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Aug. 31, 2012 | In Use |
Found 10,000 results in 6 milliseconds — Export these results